| Aug 6 |
Acadia Pharmaceuticals Reports Second Quarter 2024 Financial Results and Operating Overview
|
| Aug 5 |
Acadia Pharma Q2 2024 Earnings Preview
|
| Aug 3 |
Analysts Expect ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) To Breakeven Soon
|
| Jul 30 |
Acadia Pharmaceuticals (ACAD) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
|
| Jul 24 |
Acadia Pharmaceuticals to Announce Second Quarter Financial Results on August 6, 2024
|
| Jul 18 |
Clinical Data from Open-Label Extension LILAC-1™ and LILAC-2™ Studies Evaluating Long-Term Safety and Efficacy of DAYBUE™ (trofinetide) in Patients with Rett Syndrome Published in Med
|
| Jun 23 |
Acadia Pharmaceuticals: Back In The Buy Zone
|
| Jun 21 |
Why Is ACADIA Pharmaceuticals Inc (ACAD) One of the Best Debt Free Halal Stocks According to Hedge Funds?
|
| Jun 18 |
Acadia Pharmaceuticals Presents DAYBUE™ (trofinetide) Real-World Evidence and Additional Data in Rett Syndrome at the 2024 International Rett Syndrome Foundation (IRSF) Annual Scientific Meeting
|
| Jun 6 |
Acadia Pharmaceuticals: Bullish On Nuplazid And Daybue Driven Growth In CNS Treatments
|
